Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arexvy
Pharma
FDA signs off on GSK's Arexvy for at-risk adults ages 18-49
GSK has scored an FDA expansion for its RSV vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease.
Kevin Dunleavy
Mar 13, 2026 11:07am
GSK's long-acting asthma med wins CHMP backing
Dec 12, 2025 11:27am
Emma Walmsley upholds £40B sales target in final GSK CEO report
Oct 29, 2025 11:14am
GSK's Emma Walmsley to step down as CEO in shock move
Sep 29, 2025 3:39am
ACIP broadens guidance for RSV vaccines from GSK, Pfizer
Apr 17, 2025 11:04am
GSK, Pfizer end RSV patent feud amid vaccine market uncertainty
Apr 4, 2025 10:55am
